Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Organizing biological data
Transcriptomic analysis of C. elegans mutants which do not respond to oomycete exposure
Clinical and Biomarker Results from A Phase II Trial of Combined Cabozantinib and Durvalumab in Patients with Chemotherapy-refractory Colorectal Cancer (CRC): CAMILLA CRC Cohort
A proof-of-concept phase 2 study of the CHK1 inhibitor prexasertib with translational study outcomes in platinum-resistant recurrent, BRCA wild-type high-grade serous ovarian carcinoma
Combining anti-PD1 and vorinostat improves anti-tumor treatment in IDH-mutant brain tumors
Differential T-cell and monocyte responses in hepatocellular carcinoma treated with regorafenib plus nivolumab: an integrated clinical and biomarker analysis of the phase 2 RENOBATE trial
Spatial immuno-oncology protein abundance profiles in hepatocellular carcinoma tissues from patients treated with bavituximab and pembrolizumab
Distinct Transcriptional Landscapes Identified by Radiographic Response in Metastatic Triple-Negative Breast Cancer Treated with Carboplatin, Nab-Paclitaxel, and Pembrolizumab in a Single-Arm Phase II Trial
Addition of atezolizumab to carboplatin significantly improves survival of patients with metastatic triple-negative breast cancer: TBCRC 043 phase 2 randomized clinical trial
Targeting of Focal Adhesion Kinase enhances the immunogenic cell death of PEGylated liposome doxorubicin to optimize therapeutic responses of immune checkpoint blockade
Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: Clinical efficacy and correlative analyses
RNA-seq of FGFR2 fusion+ ICC cell lines (ICC21 and ICC10-6) treated with Infigratinib or/and Afatinib against untreated control
Biological effect of azacitidine (CC-486) on peripheral T-cell lymphoma
Sitravatinib Plus Nivolumab in Patients Undergoing Nephrectomy for Locally Advanced Clear Cell Renal Cell Carcinoma
RNA-seq of plasmatocytes after septic injury
Autologous SPEAR T-cell therapy in MAGE-A4 positive solid cancers: a Phase 1 trial of afamitresgene autoleucel in HLA-A*02 positive patients
Hepatic Tumor Stiffness Measured by Shear Wave Elastography is Prognostic for HCC Progression Following Treatment with Anti-PD-1 Antibodies plus Lenvatinib: A retrospective analysis of two independent cohorts
A phase 2, open label single arm study for evaluating safety & efficacy of apremilast in the treatment of cutaneous disease in patients with recalcitrant dermatomyositis.
The BAMM Trial: BRAF, Autophagy and MEK inhibition in Metastatic Melanoma: A phase I/II trial of dabrafenib, trametinib and hydroxychloroquine in patients with advanced BRAF mutant melanoma
Afatinib and Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ALPHA Study): A Phase II Study with Biomarker Analysis
Rhodanobacter denitrificans strain:FW104-MT042
Rhodanobacter denitrificans strain:FW104-MT042 Genome sequencing
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on